Overview

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
Phase:
Phase 2
Details
Lead Sponsor:
Ocular Therapeutix, Inc.